MicroRNAs: immune modulators in cancer immunotherapy

Yun Xing¹,†, Zhiqiang Wang²,†, Zhou Lu²,³, Jie Xia¹, Zhangjuan Xie¹, Mengxia Jiao¹, Ronghua Liu¹,† and Yiwei Chu¹,²,*

¹Shanghai Fifth People’s Hospital and Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China, ²Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, P.R. China and ³Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai 200032, P.R. China

*Correspondence: Yiwei Chu, Department of Immunology, School of Basic Medical Sciences, and Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, No.138, Yi Xue Yuan Rd., Shanghai 200032, P.R.China. Email: yiweichu@fudan.edu.com

†These authors contributed equally to this work.

Received 24 March 2021; Revised 18 April 2021; Accepted 7 May 2021

Summary

MicroRNA (miRNA) is a class of endogenous small non-coding RNA of 18–25 nucleotides and plays regulatory roles in both physiological and pathological processes. Emerging evidence support that miRNAs function as immune modulators in tumors. MiRNAs as tumor suppressors or oncogenes are also found to be able to modulate anti-tumor immunity or link the crosstalk between tumor cells and immune cells surrounding. Based on the specific regulating function, miRNAs can be used as predictive, prognostic biomarkers, and therapeutic targets in immunotherapy. Here, we review new findings about the role of miRNAs in modulating immune responses, as well as discuss mechanisms underlying their dysregulation, and their clinical potentials as indicators of tumor prognosis or to sensitize cancer immunotherapy.

Keywords: microRNAs, immunomodulation, cancer immunotherapy

Abbreviations: ACT: Adoptive cell therapy; CRC: Colorectal cancer; CTL: Cytotoxic (CD8+) T cell; DCs: Dendritic cells; EMT: Epithelial-mesenchymal transition; Foxp3: Forkhead box P3; gCSC: Glioma cancer stem cells; ICB: Immune checkpoint blockade; IgA: Immunoglobulin A; IKKs: I-kappaB kinases; miRNA: MicroRNA; ncRNAs: Non-coding transcripts; NSCLC: Non-small-cell lung cancer; PTX: Paclitaxel; RISC: RNA-induced silencing complex; RNApolII: RNA polymerase; Treg: Regulatory T; TEX: Tumor-derived exosomes; UTR: Untranslated region.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Cancer development and progression are accompanied by complex immune responses [1, 2]. As a new and promising treatment after traditional cancer therapies (surgery, radiotherapy, and chemotherapy), immunotherapy has gradually caught people's attention and recognition since 1945. It has been abundantly confirmed in murine tumor models as well as in humans and has become a pivotal treatment for various cancers. It depends on inducing an anti-tumor immune response by small molecule drugs or biological medicine to remove tumor and cure patients, which achieves non-invasive, safe, targeted specifically, and lower side effects. The objective of immunotherapy is to trigger and elevate specificity and longer memory of adaptive immune response, attaining tumor regression and therapeutic effects. Tumor immunotherapy commonly utilizes active and passive strategies. Active immunotherapy adopts anti-tumor vaccines to induce and enhance the specific immune response against tumor antigens. Instead, passive immunotherapy selects a more direct and rapid approach to rebuild immune systems by delivering antibodies or lymphocytes with anti-tumor activity. Up to now, there are mainly three methods including adoptive cell therapy (ACT), tumor vaccines, immune checkpoint blockade (ICB) immunotherapy, and so on. All these therapies have led to important clinical advances and achieved great success.

MicroRNA (miRNA) is a class of endogenous small non-coding RNA of 18–25 nucleotides long. Early in 1993, Lee RC et al. first found that the small RNA encoded by lin-4 gene in nematode [3]. Since then, multiple kinds of miRNAs and their corresponding targets have been screened and identified. Most of them are highly conserved across different species and have reported as important regulators both in physiological and pathological processes. More than 60% of human protein-coding genes are predicted to be under selective pressure to be regulated by miRNAs and involve in complex cellular processes, including development, proliferation, differentiation, apoptosis, and stress response [4, 5]. MiRNAs also play a central role in immune system, a vital defense system of body [6, 7]. Increasing evidence focusing on tumors explored miRNAs as key regulators in balancing immune response to control initiation and development of diseases, as well as new discovery of their new function mode and potential clinical significance in immunotherapy.

Biogenesis and action mode of miRNAs

MiRNA biogenesis and its function in cytoplasm

MiRNAs are encoded within intergenic regions or within the introns or exons of protein-coding genes of the genome. Generally, after transcription, cleavage, and processing, mature miRNAs are transported from the nucleus to cytoplasm to be loaded into RNA induced silencing complex (RISC) [8, 9]. The cornerstone of the miRNA functioning is the formation of the RISC comprising minimally of an AGO protein and a miRNA molecule. In which, miRNA base pairs with the 3’ untranslated region (UTR) of mRNA, mediating target mRNA decay or detachment of ribosomes [10]. While, there are some miRNAs, like miR-10a, that can interact with the 5’ untranslated region of miRNAs to enhance their translation [11] (Fig. 1A).

Transcriptional regulation by miRNAs in nucleus

Besides, miRNA in nucleus can also regulate their targets at the transcriptional level. It is through complementarity binding to the genic regions, especially the promoter, or to the non-coding transcripts (ncRNAs) derived from the promoter region [12–14]. These bindings may increase expression of protein-coding genes. For instance, human miR-373, as an activator of gene transcription induced both E-cadherin and cold-shock domain-containing protein 2 [15]. Possible mechanism underlying is via induction of binding and activity of RNA polymerase (RNAPolII) other chromatin modifiers like DNMTs, HDAC, and EZH2. Several components of RISC may be also involved in this process, especially AGO proteins [12, 13, 15–19] (Fig. 1A, a–b). It is interesting to note that a group of miRNAs, termed ‘epi-miRNAs’, has been reported to reciprocally modulate epigenetic regulators, suggesting the existence of a regulatory circuit between miRNAs and epigenetic modifiers [20, 21] (Fig. 1B). Liu suggested the epigenetic circuit of miR-126-DNMT1, in which, DNMT1, critical for gene-specific methylation, was highly expressed in esophageal cancer tissues and responsible for the hypermethylation of the promoter of miR-126 host gene and the subsequent silence of miR-126, whereas, overexpression of miR-126 feedback suppressed DNMT1 expression [20]. The ‘epi-miRNAs’ provides the evidence to support not only epigenetic modulations on miRNA expression but also epigenetic crosstalk between epigenetics and miRNAs.

Function of miRNAs in tumor-infiltrating immune cells and their crosstalk with tumor cells

Since the first discovery of miR-15a/16-1 cluster as the tumor-suppressor in chronic lymphocytic leukemia, tumor-related miRNAs have received unprecedented attention. More than 50% of human miRNAs have been reported to be located at sites of chromosomes that are always abnormal in cancer, such as gene deletion, rearrangements, amplification, or translocation...
during carcinogenesis [5]. Altered miRNA profiles have been reported in multiple cancers, and they can directly regulate tumor cell biology including cell proliferation, apoptosis, migration, as well as stemness. Function of miRNAs can be tumor-promoting or suppressive, which depends on their targets, and always involves synergy of several targets [22–24]. We reported miR-126 suppressed esophageal cancer cell proliferation and migration by interacting with ADAM9 mRNA 3′UTR [20]; while, both anti-apoptosis protein BLC2 and cell-cycle-related protein PA28gamma were the targets of miR-7 in non-small-cell lung cancer (NSCLC) [25, 26]. More importantly, different from the previous knowledge that miRNA directly regulates tumor cell biology, our recent evidence revealed the role of tumor-related miRNAs in modulating anti-tumor immunity, and in linking crosstalk between tumor cells and immune cells surrounding, as well as discovered mechanisms underlying their dysregulation during tumorigenesis (Fig. 2A–C).
MiRNAs modulate anti-tumor activity of tumor-infiltrating immune cells

The role of tumor-related miRNAs in modulating anti-tumor immunity has gained more attention as immunotherapies entering clinic for tumor eradication. MiR-15a and miR-16-1 are previously reported to function by directly regulating tumor cell biology including cell proliferation, cell apoptosis, and cell cycle [27] (Fig. 2A).

Our recent work reveals the novel role of tumor-related miR-15a/16-1 cluster in modulating CD8+ T cell (CTL)-mediated anti-tumor activity and thereby controlling tumor development [28]. MiR-15a/16-1 was increased in CTLs in mice bearing GL261-derived glioma. The miR-15a/16-1-deficient CTLs in glioma showed higher active phenotypes, more cytokines secretion and faster expansion. They had lower expression of exhausted T cells and higher production of pro-inflammatory cytokines such as IFN-γ.

Figure 2: New findings in tumor reveal miRNAs as immune regulators. (A) MiR-15a/16-1 is increased in CD8+ T cells of glioma tissues, which results in reduction of anti-tumor effect but induction of exhaustion of CD8+ T cells. mTOR is the key target of miR-15a/16-1 in this process. (B) MiR-15a/16-1 cluster is downregulated in neoplastic epithelial cells, which cause infiltration of immunosuppressive B cells into neoplastic tissues, and subsequent inhibition of anti-tumor effect of CD8+ T cells. In mechanism, miR-15a/16-1 could inhibit epithelial production of CXCL9 and CXCL10 by targeting I-kappaB kinases (IKKs)-NF-κB/STAT1 signaling. Decrease of miR-15a/16-1 in epithelial cells was triggered by IL-17A, and its decrease can upregulate IL-6 expression in an NF-κB-dependent manner to maintain Th17 cell differentiation. (C) Tumor-derived exosomes transport and delivery miRNAs into tumor infiltrating immune cells, possibly modulating their immunosuppressive function. Several exosomal shuttle miRNAs can act as ligands of Toll-like receptors (TLRs), triggering secretion of tumor-promoting and inflammatory mediators. (D) miRNA function in inflammatory response, and there is an opposite effect on LPS-induced macrophage response between miR-34a and miR-155. Aryl hydrocarbon receptor (AHR) is the direct target of miR-15a/16-1 in CD4+ T cells. Decreasing miR-15a/16-1 in CD4+ T cells can ameliorate inflammatory tissue injury in an IL-22-dependent manner. As a synergistic effect, decrease of miR-15a/16-1 level in damaged hepatocytes contributes to IL-22-mediated tissue repair by reducing cell apoptosis and promoting cell proliferation.
markers including PD-1, Tim-3, and LAG-3, but stronger secretion of anti-tumor factors including IFN-γ and TNF-α, indicating more sensitive to immune checkpoint blockade therapy as well as owning more active immune responses. In mechanism, mTOR was identified as the target of miR-15a/16.

Other research has also revealed several miRNAs and their function in tumor-infiltrating T cells. MiR-23a and miR-130/301 display inhibiting effects on CTL immune responses [29, 30]; while, miR-17/92, miR-21, miR-124, and miR-155 can promote the maturation of CTL cells into effector or memory cell subsets [31–36]. For instance, miR-21 could activate CTL cells via the PTEN/Akt pathway in response to stimulations; while upregulating miR-23a reduced CTL expression of anti-tumor effector molecules, including granzyme B and IFN-γ by targeting BLIMP-1 [29]. Additionally, Dudda JC et al. showed that Mir155(-/-) CD8(+) T cells were ineffective at controlling tumor growth, whereas miRNA-155 overexpression enhanced the antitumor response [37]. Moreover, miRNA roles have been also elucidated in regulatory T (Treg) cell biology, with particular attention to miR-124, miR-142-3p, miR-146a, and miR-155, several of which may be regulated by forkhead box P3 (Foxp3) [31, 38–41]. Some of them are involved in balancing effective and regulatory function of tumor-infiltrating T cells to maintain the anti-tumor immune homeostasis, which would provide a new insight in cancer immunotherapy.

**Tumor-tirggered remodeling of immune microenvironment regulated by miRNAs**

Since 2011, inflammation is considered as a hallmark of cancer. Several miRNAs, such as miR-126, miR-21, miR-34, miR-155, miR-146, miR-15, miR-16, and so on have been identified as regulators of inflammatory processes and inflammation-associated diseases [42, 43]. One miRNA plays a role in diverse inflammation-associated diseases [44, 45], and an inflammatory disease is regulated by a pattern of miRNAs [46, 47]. Numerous miRNAs exert function in the regulation of pro-inflammatory and anti-inflammatory pathways, particularly, TLR, NF-κB, and TGF-β pathways [1, 43, 48]. Some other miRNAs participate in activation of both innate and adaptive immune cells including macrophages, neutrophils, T cells, B cells, and so on [42, 49]. Our recent work identifies new role of miRNAs in modulating innate and adaptive immune response as well as provides new insight in exploring inflammatory injury repair (Fig. 2D).

We proved evidence supporting inflammation-triggered dysregulation of miRNAs. Take miR-15a/16-1 as an example, we identified miR-15a/16-1 as a linker between colitis and colorectal cancer [50]. MiR-15a/16-1 in epithelia cells was downregulated during tumorigenesis and reconstructed the immunosuppressive microenvironment to facility tumor progress. More importantly, we found that IL-17 was increased in this process and responsible for the dysregulation of miR-15a and 16-1, which was NF-κB signaling dependent (Fig. 2B). Similarly, Omrane et al. showed that in the immune microenvironment of colorectal tumor, miRNAs including miR-21, miR-146a, and miR-155 belong to the Th17 pathway [51]. Moreover, we reviewed other studies and found that miR-142-5p and miR-130a-3p were regulated by IL-4 and IL-13 in macrophages in chronic inflammation, microRNA-146a was interleukin 1β responsive in THP-1 cells, and miR-23a could be upregulated by TGF-β in tumors [52–54]. These data suggest that inflammatory mediators are also important factors in triggering miRNAs disorders.

MiRNAs in tumor cells can alter percentage or function of immune cells surrounding to construct the comfortable ‘soil’ for the growth of the tumor itself. Our reports in colorectal cancer (CRC) illustrated that downregulation of miR-15a/16-1 cluster in neoplastic epithelial cells reconstructed the immunosuppressive microenvironment to facility tumorigenesis [50] (Fig. 2B). A decrease of miR-15a/16-1 in epithelia cells caused more tumor-infiltrating B cells. B cells are known as antibody producers and play in humoral immunity, we found a higher immunoglobulin A (IgA) positive in CRC-infiltrating B cells. The IgA+B cells highly expressed suppressive factors like IL-10, TGF-β, and PD-L1 and facilitated tumor progress by repressing the proliferation and activation of CD8+ T cells. Moreover, IgA+B cells expressed more CXCR3, which were likely to be recruited by miR-15a/16-deficient tumor cells. In mechanism, I-kappaB kinases (IKKs), especially IKKE and IKKB was identified as the targets of miR-15a/16, and overexpressing miR-15a/16-1 in epithelial cells suppressed CXCL9 and CXCL10 secretion by downregulating IKKs expression and the subsequent activation of STAT1 and NF-κB signaling. Increasing miR-15a/16-1 restrained infiltration of these immunosuppressive B cells into colorectal cancer (CRC), resulting in repression of CRC. The negative correlation between levels of miR-15a/16 and numbers of IgA+B cells was found in human CRC tissues; high levels of miR-15a/16 and low numbers of IgA+B cells might be indicators for longer survival times of CRC patients. Based on these findings, the use of miRNA mimics to modulate immunosuppressive B cell accumulation is a potential new therapeutic strategy for combatting colorectal cancer.
Similar to this study, other miRNAs were also reported to function in remodeling immune cells in tumor microenvironment. For instance, deregulation of miR-34a in portal vein tumor thrombosis remodeled the tumor microenvironment through manipulation of Tregs [55]; in which, the Treg recruitment chemokine CCL-22 was a target of miR-34a. Upregulating miR-124 in glioma cancer stem cells (gCSC) reversed gCSC-mediated immunosuppression of T-cell proliferation and induction of Foxp3+ Treg [31]. Additionally, miR-126/126* pair was reported to be able to modulate the composition of the microenvironment of primary tumors in order to contrast breast cancer metastasis by regulating CCL2 expression of cancer cells in an SDF-1α-dependent manner [36].

In addition to affecting the recruitment of immune cells, miRNAs in tumors can alter the immune cells surrounding by targeting checkpoints, of which, PD-L1 is the outstanding target. The relationships among miRNAs, PD-L1, and tumor-infiltrating lymphocytes have been investigated. In acute myeloid leukemia, tumor suppressor MiR-34a targeted PD-L1 and functioned as a potential immunotherapeutic target [57]. Overexpression of miR-142-3p could also inhibit PD-L1 expression on tumor cells, which resulted in the increase of IFN-γ and TNF-α secreting CD8+ T lymphocytes [58]. Moreover, by targeting PD-L1, the suppressive role of miR-140 was associated with the increased infiltrating of myeloid-derived suppressive cells and regulatory T cells [59]. Other microRNAs including miR-574, miR-570, miR-513, miR-197, miR-34a, and miR-200 have also been proven to negatively regulate PD-L1 as a novel role of pro-survival signaling in cancer [60].

**Exosomal shuttle miRNAs involve in crosstalk between tumor cells and immune cells**

MiRNAs in the tumor can also be transferred from tumor cells to the surrounding immune cells, thus changing the immune response, in which, exosomes are the important carrier and transporter. Exosomes are 30–100 nm in diameter, with a classic ‘cup’ or ‘dish’ morphology, contain proteins and genetic massages like miRNAs, DNA fragments, and microRNAs [61]. These exosomal shuttle miRNAs can be shuttled from a donor cell to recipient cells to affect their activation and function [62]. Our recent ongoing research in colorectal cancer showed miRNA profiles in tumor-derived exosomes (TEX) were distinguished with that from normal epithelia cells. The up-regulated miRNAs like miR-135b, miR-146a, and miR-150 were enriched in tumor infiltrating B cells, possibly modulating their immunosuppressive function (Fig. 2C). Tumor-immune crosstalk can be mediated by soluble factors (contact-independent) and ligand-receptor pairs (contact-dependent).

As support, Zhou et al. found that exposure of dendritic cells (DCs) to pancreatic cancer derived exosomes caused downregulation of TLR4-induced production of cytokines necessary for the maturation and function of DCs, for which, miR-203 secreted into exosomes was responsible [63]. Moreover, other TEX miRNAs, including miR-212-3p, miR-451, miR-214, miR-292a, miR-210, and miR-23a have been also reported to regulate tolerance of DCs, T cell differentiation and NK-/NKT cell-mediated cytotoxicity [64]. Other new evidence shows that miRNA transported by TEX can act as TLR’s ligands. For instance, oncogene miR-21 and miR-29a secreted into exosomes by NSCLC cell or neuroblastoma could bind to Toll-like receptors TLR7 and TLR8, triggering the secretion of pro-metastatic inflammatory cytokines [65]. Moreover, taking miR-210, miR-23a, and miR-451 as examples, release of TEX-miRNAs might be triggered by the hypoxic or glucose-deficient tumor microenvironment [66–68].

**Clinical potential of miRNAs in modulating cancer immunotherapy**

**Potential in predicting cancer survival and sensitizing chemotherapy**

MiRNAs have shown exciting potential application in predicting survival and cancer therapy. We found that tumor-suppressive miR-126 was of lower level in esophageal cancer tissues, which was correlated with short survival time of patients, implying their potential function as a prognosis indicator [20]. Notably, research from Jian Zhou et al. with independent validation in a large cohort of 934 participants identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) that provided a high diagnostic accuracy of HCC [69].

MiRNAs in tumors, such as miR-221/222, miR-328, miR-326, and miR-34a have been reported to alter chemosensitivity of cancer cells [70]. We found miR-7 was upregulated in paclitaxel (PTX)-treated NSCLC cells and identified increasing miRNA-7 sensitizes NSCLC cells to PTX therapy by targeting EGFR [71]. Similarly, Exosomes containing miR-122 combined with sorafenib treatment and significantly reduced HepG2 tumors [72]. These results provide evidence supporting for altering endogenous level of miRNAs may be a potential therapeutic strategy for adjuvant chemotherapy of cancer, and exosomes may be used as a carrier.
Potential in modulating cancer immunotherapy

In recent years, the research of microRNA connected with immunotherapy is heated and achieved remarkable results. The discovery and clinical application of PD-1 and CTLA-4 successfully caught people’s attention to ICB immunotherapy and opened a new era of immunotherapy (Fig. 3). So far, the inhibitory immune signals found on the surface of T cells include CTLA-4, PD-1, LAG-3, TIM-3, VISTA, BTLA, and so on. Although ICB has led to important clinical advances and achieved great success because of the durable responses and enhancement of survival rates in skin cancer, lung cancer, kidney cancer, and so on, many clinical studies indicated that there are still a large number of patients showing no response and resistant to the treatment. Therefore, it is necessary to find efficient predictive biomarkers for better patient selection, and prognostic biomarkers to measure the outcomes.

Mir-33a with tumor-suppressive ability directly interacts with 3′UTR in mRNA of PD-1 and PD-L1 leading to decreasing the expression of the two genes. Boldrini et al. identified that patients suffering lung cancer would have a favorable outcome with a low level of PD-1 and high expression of mir-33a indicating that the potential of mir-33a is a good prognostic biomarker [73]. In contrast with mir-33a, mir-20b, mir-21, and mir-130b are oncogenic and overexpressed in colorectal cancer cells (CRC). Overexpressed mir-20b, mir-21, and mir-130b inhibit the expression of PTEN, a PI3K/AKT signaling pathway suppressor, which in turn upregulates PD-L1 achieving tumorigenesis [74]. Therefore, the three microRNAs seem to indirectly regulate PD-L1. Among them, mir-21 relying on the character of circulating in blood is more favored by people, and can be seen as a potential noninvasive predictive biomarker in tumor immunotherapy [75].

Moreover, miRNA can be the therapeutic target to enhance the efficiency in ICB immunotherapy dependent on their interaction with immune checkpoints. There are seven tumor suppressor microRNAs targeting PD-L1 including miR-34a, miR-200, miR-570, miR-513, miR-138-5p, miR-424-5p, and miR-197 which can be the immune checkpoint inhibitors. They all suppress expression of PD-L1, suggesting that delivering these microRNAs or their mimics can enhance immune response for tumor to reach the therapeutic aim [76–80]. In addition, miRNA has functions to impede tumor immune escape, but also prevent metastasis. miR-200 is known as a repressor of EMT (epithelial-mesenchymal transition through, a critical driver for metastasis) by negatively regulating ZEB1 and ZEB2 (E-cadherin Transcriptional Repressors), as well as can directly modify PD-L1 expression in tumor cells [81]. For mesothelioma patients, low levels of mir-200 have been identified to related to high PD-L1 levels and poor prognosis, suggesting the potency for prediction [82, 83]. And the same situation appears in NSCLC and indicates that early-stage NSCLC patients with the expression of miR200/PD-L1 axis may be beneficial.

Figure 3 The application of miRNAs in immune checkpoint blockade immunotherapy. The immune checkpoints on the surface of T cells and their ligands expressed on tumor cells or APCs are all modulated by miRNAs. The illustration shows the relationship between these miRNAs and their targets. T type dotted line indicates suppression; black solid arrows indicate upregulation.
### Table 1  The clinical values of MicroRNA include predictive, prognostic, and therapy in immunotherapy

| Application       | MiRNAs                  | Cancer type                  | Effect of MiRNAs                                                                 | References |
|-------------------|-------------------------|------------------------------|---------------------------------------------------------------------------------|------------|
| **Predictive value** | miR-18b, miR-27a        | Hepatitis C-related          | Serum miRNA-27a and miRNA-18b are correlated with metastasis and outcome.       | [89]       |
|                   | miR-21                  | Hepatocellular carcinoma     | MiR-21 enhances resistance to IFN-α and 5-FU therapy.                           | [90]       |
|                   | miR-26a                 | Cholangiocarcinoma           | Serum miR-26a is related with metastasis of CCA.                               | [91]       |
|                   | miR-122                 | Hepatocellular carcinoma     | Low level of MiR-122 predicts a weak immune response to IFN therapy.           | [92]       |
|                   | miR-125b                | Rectal adenocarcinoma        | High level of tissue and serum miR-125b suggests poor efficiency of treatment in Locally Advanced Rectal Cancer. | [93]       |
|                   | miR-216a, miR-216b      | Glioblastoma                 | High level of miR-216 predicts longer survival after DC vaccination immunotherapy. | [94]       |
|                   | miR-3753p               | Ovarian clear cell carcinoma | Serum miR-3753p, miR-193a-5p, and miR-1228-5p indicate immune response after GPC3 vaccine therapy. | [95]       |
|                   | miR-193a-5p, miR-1228-5p| Metastatic colorectal cancer | Plasma miR-6826 and miR-6875 are negative biomarkers to evaluate vaccine treatment. | [96]       |
| **Prognostic value** | MiR-15a/16, miR-17-5p   | Colorectal cancer            | Reduction of MiR-15a/16 relates poor prognosis                                 | [27]       |
|                   | miR-26                  | Hepatocellular carcinoma     | MiR-17-5p upregulates PD-L1, causing resistant to BRAFi or MEKi.              | [97]       |
|                   | miR-33a                 | Lung adenocarcinoma          | High miR-126 expression relates to longer overall survival.                    | [98]       |
|                   | miR-129                 | Bladder Cancer               | MiR-33a via PD-1/PD-L1 regulation becomes a positive prognostic marker in lung cancer. | [99]       |
|                   | miR-138-5p, miR-142-5p  | Colorectal cancer            | High expression of miR-129 is related to poor outcome.                         | [100]      |
|                   | miR-148a-3p, miR-148b-3p, miR-152-3p | Breast cancer           | Low level miR-138-5p is related with short survival.                          | [101]      |
|                   | miR-323                 | Glioblastoma multiforme      | High expression of miR-326/miR-130a predict good outcome; low expression of miR-323/miR-329/miR-155/miR-210 predict long survival. | [102]      |
|                   | miR-326, miR-329        | Gallbladder cancer           | Low expression of miR-218-5p related to poor outcome.                         | [103]      |
|                   | miR-130a, miR-155, miR-210 | Mesothelioma               | Low levels of miR-200 related to high PD-L1 levels and poor prognosis, suggesting the potency for prediction. | [83]       |
from utilizing miR-200 mimics to block PD-L1 \([77, 83]\). Moreover, miR-200 has the ability to impede tumor immune escape via activating P53 by targeting zinc-finger E-box-binding homeobox 1. miR-138 also has the function in preventing metastasis by lowering vimentin expression, and can inhibit the expression of PD-1 and CTLA-4 on the surface of effector and regulatory T cells \([84]\). Wei et al. administered miR-138 to murine gliomas and observed tumor shrinking, the phenomenon continued even after stopping delivering miR-138, indicating the therapeutic effect of miR-138 \([85]\). In ovarian cancer, miR-424(322) expression is not only inverse association with PD-L1 and CD80, but also highly related to chemoresistance. miR-424 overexpression attenuated CD80/CTLA-4 signaling pathway via inhibiting CD80 levels on antigen presenting cells, especially dendritic cells (DCs), thereby reversing the sensitivity of epithelial ovarian carcinoma and promoting T cell immune response and anti-cancer effect \([77, 86]\). MiR-28 is an Intriguing tumor-suppressive miRNA which was found in exhausted PD-1+ T cells and caused concern because of the 30% reducing expression in melanomas. After research, miR-28 shows ability to restore the function of T cells to secrete cytokines IL-2 and TNF-\(\alpha\) by blockage PD-1, CTLA-4, TIM3, and BTLA, demonstrating the potency to be the cancer therapeutic target \([87]\). The clinical values of other miRNA are shown in Table 1.

**Conclusion**

Given that both miRNAs and immune system function in a variety of physiological and pathological processes, considering this point, it is not surprising that miRNAs function as cancer immune modulators. Altered profiles of miRNAs have been reported in multiple cancers, and identified as tumor suppressor or oncogenic depending on their targets. More importantly, tumor-miRNAs affect tumorigenesis not only directly by regulating tumor cell biology including cell proliferation apoptosis and cell cycle, but also by modulating anti-tumor immunity, and linking the crosstalk between tumor cells and immune cell. Moreover, accumulating evidence has also explained the mechanisms underlying dysregulation of tumor-related miRNAs, in which, we found that persistent inflammatory stimulation is the key inducer, and epigenetic modifications including DNA methylation, histone acylation, and even posttranslational modifications are involved. Together, they form a complex epigenetic network in tumor. Due to their significant function, some of miRNAs have been highlighted as indicators of tumor prognosis, or as potential modulators in cancer immunotherapy. MRX34, the first replacement therapy based
on miRNA, is a liposomal-nanoparticle-based miR-34a mimic that has entered into Phase I clinical trial for liver cancer treatment and displayed some bright and promising responses, however, finally withdrawal the drug from the trial due to general toxicity. Therefore, another important aim of miRNA therapy is to develop a safe and powerful delivery vector system [77, 88].

Acknowledgments
The Editor-in-Chief, Tim Elliott, and handling editor, Tao Dong, would like to thank the two anonymous reviewers for their contribution to the publication of this article.

Funding
This work was supported by the National Science Foundation of China (81730045, 81972666), Shanghai Rising-Star Program (19QA1406900), Shanghai Municipal Commission of Health and Family Planning (2018YQ16, 2018Y0089), and Innovative Research Team of High-level Local Universities in Shanghai.

Author contributions
Y.X.: Data curation, formal analysis, methodology, visualization, writing original draft, writing review, and editing. Z.W.: methodology, resources, software, writing review, and editing. Z.L., J.X., Z.X., and M.J.: methodology, software, and visualization. R.L. and Y.C.: Conceptualization, funding acquisition, project administration, supervision, writing and reviewing, and editing.

Conflict of interest
The authors have declared that no conflict of interest exists.

Data availability
No new data were generated or analyzed in support of this research.

References
1. Quintanilha BJ, Reis BZ, Duarte GBS et al. Nutrimiromics: role of microRNAs and nutrition in modulating inflammation and chronic diseases. Nutrients 2017;9(11):1168.
2. Zhong H, Ma M, Liang T et al. Role of MicroRNAs in obesity-induced metabolic disorder and immune response. J Immunol Res 2018;2018:2835761.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843–54.
4. Friedman RC, Farh KK, Burge CB et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92–105.
5. Mingardi J, Musazzi L, De Petro G et al. miRNA Editing: New insights into the fast control of gene expression in health and disease. Mol Neurobiol 2018;55:7717–27.
6. Singh RP, Massachi I, Manickavel S et al. The role of miRNAs in inflammation and autoimmunity. Autoimmun Rev 2013;12:1160–5.
7. Curtale G. MiRNAs at the crossroads between innate immunity and cancer: focus on macrophages. Cells 2018;7(2):12.
8. Kim YK, Wang D, Kim SV. Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesis. Proc Natl Acad Sci USA 2016;113:E1881–9.
9. Ding XC, Weiler J, Grosshans H. Regulating the regulators: mechanisms controlling the maturation of microRNAs. Trends Biotechnol 2009;27:27–36.
10. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2009;10:92–14.
11. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008;30:460–71.
12. Liu H, Lei C, He Q et al. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer 2018;17:64.
13. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci 2016;17(10):1712.
14. Meng X, Jiang Q, Chang N et al. Small activating RNA binds to the genomic target site in a seed-region-dependent manner. Nucleic Acids Res 2016;44:2274–82.
15. Place RF, Li LC, Pookot D et al. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008;105:1608–13.
16. Wu C, Liu Z, Ma L et al. MiRNAs regulate oxidative stress related genes via binding to the 3' UTR and TATA-box regions: a new hypothesis for cataract pathogenesis. BMC Ophthamol 2017;17:142.
17. Zhang Y, Fan M, Zhang X et al. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs. Rna 2014;20:1878–89.
18. Huang V, Place RF, Portnoy V et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012;40:1695–707.
19. Pisignano G, Napoli S, Magistri M et al. A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers. Nat Commun 2017;8:15622.
20. Liu X, Jiang X, Liu R et al. B cells expressing CD11b effectively inhibit CD4+ T-cell responses and ameliorate experimental autoimmune hepatitis in mice. Hepatology 2015;62:1563–75.
21. Wang Z, Yao H, Lin S et al. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 2013;331:1–10.
22. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006;25:6188–96.
23. Wang Y, Wang L, Chen C et al. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer 2018;17:22.

24. Zhang B, Pan X, Cobb GP et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1–12.

25. Xiong S, Zheng Y, Jiang P et al. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 2011;7:805–14.

26. Xiong S, Zheng Y, Jiang P et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer 2014;110:353–62.

27. Huang E, Liu R, Chu Y. mRNA-146a and/or in vitro-expanded human Treg cells. Immunotherapy Advances 2017;85:73–91.

28. Yang J, Liu R, Deng Y et al. MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. Int J Cancer 2017;141:2082–92.

29. Lin R, Chen L, Chen G et al. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest 2014;124:5352–67.

30. Zhang N, Bevan MJ. Dicer controls CD8+ T-cell activation, migration, and survival. Proc Natl Acad Sci USA 2010;107:21629–34.

31. Wei J, Wang F, Kong LY et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013;73:3913–26.

32. Ji Y, Wrezinski C, Yu Z et al. MiR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci USA 2015;112:476–81.

33. He W, Wang C, Mu R et al. MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles. Oncogene 2017;36:4212–23.

34. Kosaka A, Ohkuri T, Ikeya M et al. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun 2015;458:549–54.

35. Zhang J, Li Y. Oncogenic miR-155 down-regulated upon activation of antitumor cytotoxic T lymphocytes by the fusion of dendritic cells with breast carcinoma cells. Eur Rev Med Pharmacol Sci 2017;21:1027–31.

36. Huffaker TB, Lee SH, Tang WW et al. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem 2017;292:18530–41.

37. Huffaker TB, Hu R, Runtsch MC et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2012;2:1697–708.

38. Lu Y, Gao J, Zhang S et al. miR-142-3p regulates apoptosis by targeting ATG16L1 in thymic-derived regulatory T cell (Treg). Cell Death Dis 2018;9:290.

39. Holmstrom K, Pedersen AE, Gad M. Analysis of miR-146a and miR-142-3p as potential markers of freshly isolated or in vitro-expanded human T cells. Scand J Immunol 2017;85:113–21.

40. Chen L, Ma H, Hu H et al. Special role of Foxp3 for the specifically altered microRNAs in Regulatory T cells of HCC patients. BMC Cancer 2014;14:489.

41. Kohlihas S, Garden OA, Scudamore C et al. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009;182:2578–82.

42. Contreras J, Rao DS. MicroRNAs in inflammation and immune responses. Leukemia 2012;26:404–13.

43. Marques-Rocha JL, Sambas M, Milagro FI et al. Noncoding RNAs, cytokines, and inflammation-related diseases. Faseb J 2015;29:3595–611.

44. Gwiggner M, Martinez-Nunez RT, Whiteoak SR et al. MicroRNA-31 and MicroRNA-155 are overexpressed in ulcerative colitis and regulates IL-13 signaling by targeting interleukin 13 receptor alpha-1. Genes 2018;9(2):85.

45. Pfeiffer D, Roßmanneth E, Lang I et al. miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model. PLoS One 2012;11:e0179850.

46. Jia P, Wu X, Dai Y et al. MicroRNA-21 is required for local and remote ischemic preconditioning in multiple organ protection against sepsis. Crit Care Med 2017;45:e703–10.

47. Huang J, Zhu L, Qiu C et al. MicroRNA miR-126-5p enhances the inflammatory responses of monocytes to lipopolysaccharide stimulation by suppressing cytokinomatosis in chronic HIV-1 infection. J Virol 2017;91(10):e02048–16.

48. Guo L, Zhang Y, Zhang L et al. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer. Tumour Biol 2016;37:115–25.

49. O’Connell RM, Rao DS, Chaudhuri AA et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111–22.

50. Liu R, Lu Z, Gu J et al. MicroRNAs 15A and 16-1 activate signaling pathways that mediate chemotaxis of immune regulatory B cells to colorectal tumors. Gastroenterology 2018;154:637–651.e7.

51. Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: Involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta 2015;1856:28–38.

52. Su S, Zhao Q, He C et al. MicroRNAs as oncogenes and pathological roles for microRNAs in the immune responses. Leukemia 2016;30:458–69.

53. Kim J, Kim TY, Lee MS et al. Exosomal cargo reflects TGF-β-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells. Biochem Biophys Res Commun 2016;478:643–8.

54. Song Y, Dou H, Li X et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis. Stem Cells Transl Med 2017;35:1208–21.

55. Yang P, Li QJ, Feng Y et al. TGF-β-miR-34a-CCL2 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012;22:291–303.
56. Zhang Y, Yang P, Sun T et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol* 2013;15:284–94.
57. Chen J, Jiang CC, Jin L et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. *Ann Oncol* 2016;27:409–16.
58. Jia L, Xi Q, Wang H et al. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. *Biochem Biophys Res Commun* 2017;488:425–31.
59. Ji X, Wang E, Tian F. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. *Biochem Biophys Res Commun* 2018;495:1342–8.
60. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 Checkpoint. *Immunity* 2018;48:434–52.
61. Ruivo CF, Adem B, Silva M et al. The biology of cancer exosomes: Insights and new perspectives. *Cancer Res* 2017;77:6480–8.
62. Zhao L, Liu W, Xiao J et al. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. *Cancer Lett* 2015;356:339–46.
63. Zhou M, Chen J, Zhou L et al. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. *Cell Immunol* 2014;292:65–9.
64. Greening DW, Gopal SK, Xu R et al. Exosomes and their roles in immune regulation and cancer. *Semin Cell Dev Biol* 2015;40:72–81.
65. Fabbri M, Paone A, Calore F et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci USA* 2012;109:E2110–6.
66. Liu LL, Li D, He YL et al. miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha. *Mol Med* 2017;23:258–71.
67. Hsu YL, Hung JY, Chang WA et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. *Oncogene* 2017;36:4929–42.
68. Liu F, Bu Z, Zhao F et al. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells. *Cancer Sci* 2018;109:65–73.
69. Zhou J, Yu L, Gao X et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. *J Clin Oncol* 2011;29:4781–8.
70. Catela Ivkovic T, Voss G, Cornella H et al. microRNAs as cancer therapeutics: A step closer to clinical application. *Cancer Lett* 2017;407:113–22.
71. Liu R, Liu X, Zheng Y et al. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. *Oncol Lett* 2014;8:2193–200.
72. Lou G, Song X, Yang F et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. *J Hematol Oncol* 2015;8:122.
98. Ji J, Shi J, Budhu A. MicroRNA expression, survival, and response to interferon in liver cancer. *Oncotarget* 2017;8:15894–911.

99. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. *Oncotarget* 2017;8:15894–911.

100. Zhao L, Yu H, Yi S et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. *Oncotarget* 2016;7:45370–84.

101. Chen X, Wang YW, Gao P. SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. *J Exp Clin Cancer Res* 2018;37:100.

102. Qiu S, Lin S, Hu D et al. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. *J Transl Med* 2013;11:10.

103. Wang H, Zhan M, Xu SW et al. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. *Cell Death Dis* 2017;8:e2770.

104. Yuan L, Zhou C, Lu Y et al. IFN-γ-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. *Cancer Lett* 2015;359:136–47.

105. Cortez MA, Ivan C, Valdecanas D et al. PD1L Regulation by p35 via miR-34. *J Natl Cancer Inst* 2016;108(1):dyi303.

106. Li Q, Xia X, Ji J et al. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1. *Oncotarget* 2017;8:33621–30.

107. Tomokuni A, Eguchi H, Tomimaru Y et al. miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. *Oncotarget* 2015;6:18631–40.

108. Liu L, Yi H, Wang C et al. miR-129b and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma. *Mol Cell Biochem* 2018;447:125–36.

109. Rashad NM, El-Shal AS, Shalaby SM et al. Serum miRNA-27a and miRNA-18b in patients with advanced solid tumors. *Invest New Drugs* 2017;35:180–8.

110. Abdelrahman MM, Fawzy EO, Bassioumi AA et al. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. *Hum Immunol* 2016;77:667–73.

111. Dou R, Nishihara R, Cao Y et al. MicroRNA let-7, T cells, and patient survival in colorectal cancer. *Cancer Immunol Res* 2016;4:927–35.